Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- DSP to Distribute iPad2 to All MRs from Jan. Next Year
October 27, 2011
- Takara Bio Upwardly Revises Profit Forecasts for 1st Half of FY2012
October 27, 2011
- Sales of Top 30 Drug Wholesalers Up 1.9% in 2010: Yano Research Institute
October 27, 2011
- Wholesalers Expecting Some Increase in Price Gap in Next Market Price Survey
October 27, 2011
- GSK CEO Thinks Highly of Premiums for New Drug Creation, Key to Attractive Market
October 26, 2011
- Nippon Chemiphar Revises Business Forecasts for 1st Half of FY2012
October 26, 2011
- Perpetuation of Premium for New Drug Development Discussed at IMS Japan Symposium
October 26, 2011
- Wakamoto Revises the Full-Year Consolidated Forecasts Expecting Deficit Reduction
October 25, 2011
- MTPC Introduces 3-level Priority for Priority Products
October 25, 2011
- “Sales of Teribone Can Reach ¥10 Bil.”: President Asano of Asahi Kasei Pharma
October 25, 2011
- Mochida Upwardly Revises Business Forecasts for 1st Half of FY2012
October 25, 2011
- Biggest Challenge Is Decline in R&D Productivity: President Hasegawa of Takeda
October 25, 2011
- IBL Signs Licensing Contact with US Firm for Lung Cancer Type Identifying Antibody
October 25, 2011
- Daiichi Sankyo, AZ Apply for Additional Indication for Nexium for Prevention of GU, DU in Patients Given Low-Dose Aspirin
October 25, 2011
- Pfizer Japan to Split Up Domestic Manufacturing Sector to Establish New Company
October 25, 2011
- Top Drug Makers Poised to Announce 1st-Half Results: Patent Expirations Could Have Big Impact
October 25, 2011
- CMIC, Medipal Set Up Joint Venture for Orphan Drugs, Develop Alliance Model
October 24, 2011
- Sales Remain Unchanged due to Domestic Market Slump Affected by Quake: Chugai Jan-Sep 2011
October 24, 2011
- MSD, Mylan Terminate Promotional Contract for Lipovas and Renivase
October 24, 2011
- Astellas Recalls Tacrolimus in Japan, Europe After Dissolution Test Standards Unmet
October 24, 2011
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…